Progestogen safety and tolerance in hormonal replacement therapy

@article{Palacios2016ProgestogenSA,
  title={Progestogen safety and tolerance in hormonal replacement therapy},
  author={S. Palacios and A. Mej{\'i}a},
  journal={Expert Opinion on Drug Safety},
  year={2016},
  volume={15},
  pages={1515 - 1525}
}
ABSTRACT Introduction: Today, it is a mandatory practice to prescribe a combination of estrogens and progestogens for menopausal women requiring hormone therapy and with a uterus. The WHI study and its reanalysis demonstrate a big difference in results between the conjugated equin estrogen (CEE) only vs.CEE plus medroxyprogesterone acetate (MPA) arms in relation with breast cancer and cardiovascular risk. The conclusion is that risk is clearly higher in the arm with MPA than in the CEE only arm… Expand
What do TSECs provide in the menopausal hormone therapy?
  • P. Llaneza, J. Calaf, +5 authors D. Lubian
  • Medicine
  • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2018
Safety and benefit considerations for menopausal hormone therapy
Hormone Replacement Therapy in a Patient with Hypogonadism and Coexisting Medical Conditions
...
1
2
...

References

SHOWING 1-10 OF 114 REFERENCES
Drospirenone and estradiol: a new option for the postmenopausal woman
  • D. Archer
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2007
Controversies concerning the safety of estrogen replacement therapy
Progestin may modify the effect of low-dose hormone therapy on mammographic breast density
Potency of progestogens used in hormonal therapy: Toward understanding differential actions
Estrogen plus progestin and the risk of coronary heart disease.
...
1
2
3
4
5
...